Michel Sadelain
Overview
Explore the profile of Michel Sadelain including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
245
Citations
26200
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Martin K, Hammer Q, Perica K, Sadelain M, Malmberg K
Nat Rev Immunol
. 2024 Apr;
24(9):680-693.
PMID: 38658708
Allogeneic cellular immunotherapies hold a great promise for cancer treatment owing to their potential cost-effectiveness, scalability and on-demand availability. However, immune rejection of adoptively transferred allogeneic T and natural killer...
12.
Zakrzewski J, Suh D, Markley J, Smith O, King C, Goldberg G, et al.
Nat Biotechnol
. 2024 Mar;
42(4):674.
PMID: 38531977
No abstract available.
13.
Eskiocak O, Chowdhury S, Shah V, Nnuji-John E, Chung C, Boyer J, et al.
bioRxiv
. 2024 Mar;
PMID: 38529506
Intestinal stem cells (ISCs) drive the rapid regeneration of the gut epithelium to maintain organismal homeostasis. Aging, however, significantly reduces intestinal regenerative capacity. While cellular senescence is a key feature...
14.
Dobrin A, Lindenbergh P, Shi Y, Perica K, Xie H, Jain N, et al.
Nat Cancer
. 2024 Mar;
5(5):760-773.
PMID: 38503896
Chimeric antigen receptor T cells have dramatically improved the treatment of hematologic malignancies. T cell antigen receptor (TCR)-based cell therapies are yet to achieve comparable outcomes. Importantly, chimeric antigen receptors...
15.
Yi F, Cohen T, Zimmerman N, Dundar F, Zumbo P, Eltilib R, et al.
bioRxiv
. 2024 Mar;
PMID: 38464085
Chimeric antigen receptor (CAR)-engineered T and NK cells can cause durable remission of B-cell malignancies; however, limited persistence restrains the full potential of these therapies in many patients. The FAS...
16.
Stephan M, Ponomarev V, Brentjens R, Chang A, Dobrenkov K, Heller G, et al.
Nat Med
. 2024 Feb;
30(6):1788.
PMID: 38418853
No abstract available.
17.
Amor C, Feucht J, Leibold J, Ho Y, Zhu C, Alonso-Curbelo D, et al.
Nature
. 2024 Feb;
627(8004):E9.
PMID: 38383793
No abstract available.
18.
van der Stegen S, Lindenbergh P, Petrovic R, Xie H, Diop M, Alexeeva V, et al.
Nat Biomed Eng
. 2024 Feb;
8(11):1500.
PMID: 38347164
No abstract available.
19.
Amor C, Fernandez-Maestre I, Chowdhury S, Ho Y, Nadella S, Graham C, et al.
Nat Aging
. 2024 Jan;
4(3):336-349.
PMID: 38267706
Senescent cells, which accumulate in organisms over time, contribute to age-related tissue decline. Genetic ablation of senescent cells can ameliorate various age-related pathologies, including metabolic dysfunction and decreased physical fitness....
20.
Jain N, Zhao Z, Koche R, Antelope C, Gozlan Y, Montalbano A, et al.
Cancer Discov
. 2023 Nov;
14(1):142-157.
PMID: 37934007
Significance: T cells engineered with CD28-based CARs possess robust effector function and antigen sensitivity but are hampered by limited persistence, which may result in tumor relapse. We report an epigenetic...